- New study warns that Trump-era cuts to federal research could jeopardize cancer drug developmentA recent study examines how recent political moves to curtail federally funded research could affect cancer drug development. The analysis notes that over the past decade biopharma companies have…
- Moderna's cancer vaccine boost lifts stock, sparks talk of Keytruda-like reachModerna’s shares surged 177% after a phase 3 topline win for its Merck‑partnered cancer vaccine, intismeran autogene, was disclosed. The data, released on Wednesday, added roughly $45 billion to Mo…